StockNews.AI
GMED
StockNews.AI
83 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.  - GMED

1. Pomerantz LLP is investigating potential securities fraud involving GMED. 2. GMED's Q1 2025 earnings missed estimates and reported a revenue decline. 3. Stock price dropped 22.96% after the disappointing earnings announcement. 4. CEO cited supply chain disruptions and deal closures as contributing factors. 5. Investors are urged to contact Pomerantz for class action participation.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock price drop following earnings suggests market concern over GMED's stability. This mirrors past incidents in the industry where poor earnings led to similar declines, often resulting in long-term investor confidence issues.

How important is it?

The investigation by a reputable firm signals serious potential issues for GMED, likely impacting investor sentiment significantly. The correlation between earnings misses and market reactions enhances the article's relevance to GMED's performance.

Why Short Term?

The immediate reaction to earnings results could lead to further volatility in GMED's stock price. Historical patterns indicate that such analyst investigations can have continuing effects until resolved.

Related Companies

MDTSYKZBH
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, Globus issued a press release reporting its financial results for the first quarter of 2025.  Among other items, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, missing consensus estimates by $27.78 million and representing a 1.4% year-over-year decline.  Globus’s President and Chief Executive Officer said that the Company’s “first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders[.]”  On this news, Globus’s stock price fell $16.64 per share, or 22.96%, to close at $55.82 per share on May 9, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.  CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News